Community Health Assessment Program in the Philippines (CHAP-P) (CHAP-P)
Primary Purpose
Diabetes Mellitus, Type 2, Hypertension
Status
Completed
Phase
Not Applicable
Locations
Philippines
Study Type
Interventional
Intervention
CHAP-P Sessions
Sponsored by

About this trial
This is an interventional prevention trial for Diabetes Mellitus, Type 2
Eligibility Criteria
Inclusion Criteria (Community Survey Participants & CHAP-P Session Participants):
- Aged 40 years of age or older
- Resident of community
Exclusion Criteria (Community Survey Participants & CHAP-P Session Participants):
- Under 40 years of age
- Resident of a different community
Inclusion Criteria (Barangay Health Workers [BHW]/Lead Local Organization [LLO] Staff)
- Must be a BHW or other LLO staff who is participating in the CHAP-P Intervention
Sites / Locations
- Ateneo de Zamboanga University
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Intervention Community
Control Community
Arm Description
Intervention communities (barangays) will receive the intervention (CHAP-P sessions).
Control communities (barangays) will receive care as usual.
Outcomes
Primary Outcome Measures
HbA1c
Mean difference in HbA1c at 6 months in the intervention group compared to the control group. Measured with the A1CNow+ point-of-care device in a community location after the completion of the in-home community survey.
Secondary Outcome Measures
Physical Activity
Mean difference in physical activity at 6 months in the intervention group compared to the control group. Measured with the International Physical Activity Questionnaire (International Physical Activity Quotient, IPAQ), included in the community survey.
Medication Compliance
Mean difference in medication compliance at 6 months in the intervention group compared to the control group. Self-reported, via community survey questions.
Blood Pressure
Mean difference in blood pressure at 6 months in the intervention group compared to the control group. Measured using a blood pressure device, the Microlife WatchBP Office Target.
Community Residents Newly Diagnosed with Diabetes
Mean difference in number of community residents newly diagnosed with diabetes at 6 months in the intervention group compared to the control group. Numbers taken from Rural Health Unit databases
Hospital admission rates
Mean difference in hospital admission rates due to diabetes and diabetes-related conditions, hypertension, myocardial infarction, stroke, congestive heart failure at 6 months in the intervention group compared to the control group. Numbers taken from central Department of Health database (12 months before and 12 month after CHAP-P implementation, and divided by mid-year population estimates)
Mortality rates
Mean difference in mortality rates due to diabetes and diabetes-related conditions, hypertension, myocardial infarction, stroke, congestive heart failure based on International Classification of Disease (ICD)-10 codes at 6 months in the intervention group compared to the control group. Numbers taken from Regional Field Health Surveillance Information Systems (measured 12 months before and 12 month after CHAP-P implementation, 6 month estimated by dividing by mid-year population estimates)
Quality of Life (EQ5D-5L)
Mean difference in quality of life at 6 months in the intervention group compared to the control group. Measured with the EuroQol-5 dimension-5 level (EQ5D-5L), included in the community survey
Knowledge about Diabetes and Hypertension
Mean difference in knowledge about diabetes and hypertension at 6 months in the intervention group compared to the control group. Measured with elements of the Health Awareness and Behaviour Tool (HABiT) included in the community survey.
Risk Factors for Diabetes
Mean difference in risk factors for diabetes at 6 months in the intervention group compared to the control group. Measured with the Finnish Diabetes Risk Score (FINDRISC), included in the community survey
Risk Behaviours for Diabetes/Cardiovascular Issues
Mean difference in risk behavhiours for diabetes/cardiovascular issues (activity, diet, smoking, alcohol, stress) at 6 months in the intervention group compared to the control group. Measured with elements of the Health Awareness and Behaviour Tool (HABiT) included in the community survey.
Perceived Concern and Understanding of Risk
Mean difference in perceived concern and understanding of risk at 6 months in the intervention group compared to the control group. Measured with elements of the Health Awareness and Behaviour Tool (HABiT) included in the community survey.
Confidence in Behaviour Change
Mean difference in confidence in behaviour change at 6 months in the intervention group compared to the control group. Measured with elements of the Health Awareness and Behaviour Tool (HABiT) included in the community survey.
Quality-Adjusted Life Years (QALYs)
Secondary; calculated from the EQ5D-5L.
Cost-effectiveness
Comparing program cost of implementing CHAP-P (collected via team tracking) and healthcare resource utilization costs (collected via self-report from participants during community survey) to percentage reduction in HbA1c and blood pressure.
Cost-utility
Cost of program and healthcare resource utilization costs per QALY
Full Information
NCT ID
NCT03481335
First Posted
March 22, 2018
Last Updated
February 25, 2021
Sponsor
McMaster University
Collaborators
Ateneo de Zamboanga University, Université de Montréal, Global Alliance for Chronic Diseases (GACD), Canadian Institutes of Health Research (CIHR), International Development Research Centre, Canada
1. Study Identification
Unique Protocol Identification Number
NCT03481335
Brief Title
Community Health Assessment Program in the Philippines (CHAP-P)
Acronym
CHAP-P
Official Title
Cluster Randomized Controlled Trial for a Community Health Promotion Program: Community Health Assessment Program in the Philippines (CHAP-P)
Study Type
Interventional
2. Study Status
Record Verification Date
February 2021
Overall Recruitment Status
Completed
Study Start Date
June 1, 2018 (Actual)
Primary Completion Date
July 1, 2019 (Actual)
Study Completion Date
December 31, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
McMaster University
Collaborators
Ateneo de Zamboanga University, Université de Montréal, Global Alliance for Chronic Diseases (GACD), Canadian Institutes of Health Research (CIHR), International Development Research Centre, Canada
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study aims to evaluate the effectiveness of the Community Health Assessment Program in the Philippines (CHAP-P), looking at the differences between communities implementing CHAP-P versus communities not implementing CHAP-P.
Detailed Description
In this study, the investigators are evaluating the effectiveness of the CHAP-P intervention in communities of the Zamboanga Peninsula, Philippines. Specifically, the investigators are looking at the difference between hemoglobin A1c (HbA1c) levels in randomly selected residents of control communities versus those in communities implementing the CHAP-P intervention. The investigators are also looking at the differences between control and intervention communities in modifiable lifestyle risk factors for diabetes, screening rates for diabetes, rates of newly diagnosed cases of diabetes, general diabetes management, and hospital admission rates, as well as the cost effectiveness of CHAP-P.
The CHAP-P intervention consists of initial and follow-up sessions where trained local volunteers (Barangay Health Workers, or BHWs) take physical measurements (blood pressure, height, weight, waist circumference) and facilitate a diabetes risk survey; based on these findings, they provide education, materials, and referrals to local health resources as needed.
The participant groups in this evaluation include those that attend CHAP-P sessions, randomly selected community members that provide consent for a survey and HbA1c testing, and community members and BHWs/other Lead Local Organization staff who provide consent for focus groups and interviews.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2, Hypertension
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
This study is a parallel 26-community cluster randomized controlled trial. A community cluster design was chosen as CHAP-P is intended as a community-level intervention. Thirteen communities (barangays) will receive the CHAP-P sessions and will be considered intervention, while the other 13 communities will receive care as usual and will be considered control. Measures of individual participants will be taken as a repeated cross-sectional sample at baseline and at six months. A community process evaluation and cost-effectiveness evaluation will also be undertaken.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
5229 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Intervention Community
Arm Type
Experimental
Arm Description
Intervention communities (barangays) will receive the intervention (CHAP-P sessions).
Arm Title
Control Community
Arm Type
No Intervention
Arm Description
Control communities (barangays) will receive care as usual.
Intervention Type
Other
Intervention Name(s)
CHAP-P Sessions
Intervention Description
Residents of intervention communities (barangays) aged 40+ are openly invited to attend CHAP-P sessions. At CHAP-P sessions, trained local volunteers (Barangay Health Workers, or BHWs) collect consent, measure blood pressure, collect other physical measurements, and conduct a survey to determine clients' risk of diabetes. Based on the findings, BHWs provide education and/or referrals. CHAP-P sessions are held twice a month, and clients are encouraged to continuing attending for ongoing follow-up and monitoring.
Primary Outcome Measure Information:
Title
HbA1c
Description
Mean difference in HbA1c at 6 months in the intervention group compared to the control group. Measured with the A1CNow+ point-of-care device in a community location after the completion of the in-home community survey.
Time Frame
Baseline, 6 months
Secondary Outcome Measure Information:
Title
Physical Activity
Description
Mean difference in physical activity at 6 months in the intervention group compared to the control group. Measured with the International Physical Activity Questionnaire (International Physical Activity Quotient, IPAQ), included in the community survey.
Time Frame
Baseline, 6 months
Title
Medication Compliance
Description
Mean difference in medication compliance at 6 months in the intervention group compared to the control group. Self-reported, via community survey questions.
Time Frame
Baseline, 6 months
Title
Blood Pressure
Description
Mean difference in blood pressure at 6 months in the intervention group compared to the control group. Measured using a blood pressure device, the Microlife WatchBP Office Target.
Time Frame
Baseline, 6 months
Title
Community Residents Newly Diagnosed with Diabetes
Description
Mean difference in number of community residents newly diagnosed with diabetes at 6 months in the intervention group compared to the control group. Numbers taken from Rural Health Unit databases
Time Frame
6 months
Title
Hospital admission rates
Description
Mean difference in hospital admission rates due to diabetes and diabetes-related conditions, hypertension, myocardial infarction, stroke, congestive heart failure at 6 months in the intervention group compared to the control group. Numbers taken from central Department of Health database (12 months before and 12 month after CHAP-P implementation, and divided by mid-year population estimates)
Time Frame
-12 months, 12 months
Title
Mortality rates
Description
Mean difference in mortality rates due to diabetes and diabetes-related conditions, hypertension, myocardial infarction, stroke, congestive heart failure based on International Classification of Disease (ICD)-10 codes at 6 months in the intervention group compared to the control group. Numbers taken from Regional Field Health Surveillance Information Systems (measured 12 months before and 12 month after CHAP-P implementation, 6 month estimated by dividing by mid-year population estimates)
Time Frame
-12 months, 12 months
Title
Quality of Life (EQ5D-5L)
Description
Mean difference in quality of life at 6 months in the intervention group compared to the control group. Measured with the EuroQol-5 dimension-5 level (EQ5D-5L), included in the community survey
Time Frame
Baseline, 6 months
Title
Knowledge about Diabetes and Hypertension
Description
Mean difference in knowledge about diabetes and hypertension at 6 months in the intervention group compared to the control group. Measured with elements of the Health Awareness and Behaviour Tool (HABiT) included in the community survey.
Time Frame
Baseline, 6 Months
Title
Risk Factors for Diabetes
Description
Mean difference in risk factors for diabetes at 6 months in the intervention group compared to the control group. Measured with the Finnish Diabetes Risk Score (FINDRISC), included in the community survey
Time Frame
Baseline, 6 months
Title
Risk Behaviours for Diabetes/Cardiovascular Issues
Description
Mean difference in risk behavhiours for diabetes/cardiovascular issues (activity, diet, smoking, alcohol, stress) at 6 months in the intervention group compared to the control group. Measured with elements of the Health Awareness and Behaviour Tool (HABiT) included in the community survey.
Time Frame
Baseline, 6 months
Title
Perceived Concern and Understanding of Risk
Description
Mean difference in perceived concern and understanding of risk at 6 months in the intervention group compared to the control group. Measured with elements of the Health Awareness and Behaviour Tool (HABiT) included in the community survey.
Time Frame
Baseline, 6 months
Title
Confidence in Behaviour Change
Description
Mean difference in confidence in behaviour change at 6 months in the intervention group compared to the control group. Measured with elements of the Health Awareness and Behaviour Tool (HABiT) included in the community survey.
Time Frame
Baseline, 6 months
Title
Quality-Adjusted Life Years (QALYs)
Description
Secondary; calculated from the EQ5D-5L.
Time Frame
12 months
Title
Cost-effectiveness
Description
Comparing program cost of implementing CHAP-P (collected via team tracking) and healthcare resource utilization costs (collected via self-report from participants during community survey) to percentage reduction in HbA1c and blood pressure.
Time Frame
12 months
Title
Cost-utility
Description
Cost of program and healthcare resource utilization costs per QALY
Time Frame
12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria (Community Survey Participants & CHAP-P Session Participants):
Aged 40 years of age or older
Resident of community
Exclusion Criteria (Community Survey Participants & CHAP-P Session Participants):
Under 40 years of age
Resident of a different community
Inclusion Criteria (Barangay Health Workers [BHW]/Lead Local Organization [LLO] Staff)
- Must be a BHW or other LLO staff who is participating in the CHAP-P Intervention
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gina Agarwal, MBBS, PhD
Organizational Affiliation
McMaster University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Fortunato Cristobal, MD, MPH, MHPEd
Organizational Affiliation
Ateneo de Zamboanga University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Ateneo de Zamboanga University
City
Zamboanga City
State/Province
Zamboanga Del Sur
ZIP/Postal Code
7000
Country
Philippines
12. IPD Sharing Statement
Citations:
PubMed Identifier
31159778
Citation
Agarwal G, Angeles RN, Dolovich L, Kaczorowski J, Gaber J, Guenter D, Arnuco FD, Lam HY, Thabane L, O'Reilly D, Agbulos RM, Arciaga RS, Barrera J, Gregorio E, Halili S Jr, Jalani N, Cristobal F. The Community Health Assessment Program in the Philippines (CHAP-P) diabetes health promotion program for low- to middle-income countries: study protocol for a cluster randomized controlled trial. BMC Public Health. 2019 Jun 3;19(1):682. doi: 10.1186/s12889-019-6974-z.
Results Reference
derived
Learn more about this trial
Community Health Assessment Program in the Philippines (CHAP-P)
We'll reach out to this number within 24 hrs